Method of alleviating bone damage with inositoltriphosphate

• US 5,057,507 A
• Filed: 01/24/1991
• Issued: 10/15/1991
• Est. Priority Date: 04/16/1986
• Status: Expired due to Fees

• Current Assignee: Perstorp AB
• Original Assignee: Perstorp AB
• Inventors: Siren, Matti
• Primary Examiner(s): Friedman, Stanley J.
• Assistant Examiner(s): Criares, T. J.
• Application Number:
  US07/645,233
• Time in Patent Office: 264 Days
• Field of Search: 514/103
• US Class Current: 514/103
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61K 33/04 Sulfur, selenium or tellurium; Compounds thereof

Abstract

A method of preventing or alleviating tissue or bone damage in mammals is disclosed. The method comprises administering, to a mammal, a tissue damage or a bone damage preventing or alleviating effective amount of a pharmaceutical composition which includes at least one isomer of inositol trisphosphate.

Claims

1. A method in preventing or alleviating bone damage comprising administering, to a mammal in need thereof, a bone damage preventing or alleviating effective amount of a pharmaceutical composition which includes at least one isomer of inositol triphosphate.

2. A method in accordance with claim 1 wherein said pharmaceutical composition includes at least one salt of an isomer of inositol triphosphate.

3. A method in accordance with claim 2 wherein said salt of said isomer of inositol trisphosphate is a sodium, a potassium, a calcium or a zinc salt.

4. A method in accordance with claim 1 wherein said pharmaceutical composition is provided in tablet form.

5. A method in accordance with claim 1 wherein said pharmaceutical composition is provided in granular form.

6. A method in accordance with claim 1 wherein said pharmaceutical composition is provided in solution form.

7. A method in accordance with claim 1 wherein said isomer is selected from the group consisting of D-myo-inositol-1,2,6-trisphosphate, myo-inositol-1,2,3-trisphosphate and L-myo-inositol-1,3,4-trisphosphate.

8. A method in accordance with claim 7 wherein said D-myo-inositol-1,2,6-trisphosphate is provided as the sodium, the potassium, the calcium or the zinc salt.